GW Pharma (GWPH) to be acquired by Jazz Pharmaceuticals (JAZZ) for about $7.2 billion

• GW Pharmaceuticals (NASDAQ:GWPH) (UK-based) was acquired by Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) for $7.6 billion. (Completed in May 2021)

  

 

 

=Jazz Pharma (JAZZ) reported earnings on Tue 26 Feb 19 (a/h)

Jazz Pharma beats by $0.61, beats on revs; guides FY19 EPS above consensus, revs above consensus

• Reports Q4 (Dec) earnings of $3.64 per share, excluding non-recurring items, $0.61 better than the S&P Capital IQ Consensus of $3.03; revenues rose 9.2% year/year to $476.46 mln vs the $459.48 mln S&P Capital IQ Consensus.
• "Our evolution as a global biopharmaceutical company continued in 2018 as we delivered another year of record revenues and made substantial progress on key milestones, including advancing multiple pre-clinical, early- and late-stage development programs. We also initiated a broad development program to generate data for Vyxeos in new AML patient populations and other hematologic malignancies," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "In 2019, our strong financial position and scalable operations provide a foundation for further growth as we focus on key regulatory approvals, planned product launches, our development pipeline and multiple initiatives to maximize our commercial portfolio."
• Co issues upside guidance for FY19, sees EPS of $14.30-15.00, excluding non-recurring items, vs. $13.98 S&P Capital IQ Consensus; sees FY19 revs of $2.05-2.13 bln vs. $2.03 bln S&P Capital IQ Consensus.

Earnings this week : Feb. 25 - March 1, 2019 (wk 9)

Earnings confirmed to report this week:

Monday (Feb 25)

• Morning: PLAN AWI CRI DORM KOS MDR TEN
• Afternoon:  ALSN APLE APTS ATH AWR BWXT CDEV CORT CRZO DDS  DRH ELGX EPR ETSY EVER FBM FRAC FRGI GSM HNI HTZ IMMU JBT KAMN KBR LDL LSI MEDP MOS NGHC NLS OFIX OKE PBPB PEB PLOW PODD QTS RCII RP RRC SHAK SNHY SYKE THC TRTX TWOU XENT

Tuesday (Feb 26)

• Morning:  AMWD ATHM AVNS AZO BCC BLD BMO BNS BPMC CBRL CLVS DISCA DSX FCN HD LGIH LNG M MNK NCI NXST PRFT RHP RLGY SAFM SDRL SERV SFL SJM SPNS SRE SSTK TA TLRA TPH TREE TRI TRXC USCR VCEL VSI WP WYND XHR
• Afternoon:  AAXN ACAD AKCA ARNA AXGN BGS BNFT CERS CGBD CIR CLGX CPE CSGP CW DRQ DVAX ELF ENPH EOG EVH FOXF FRPT FTR GWPH HEI HPR HURN HY ICFI IMAX IMMR INGN INN INSP JAZZ JBGS MASI MED MELI MGRC MMSI MTDR MYL NBR OAS ORA OUT PANW PEN PLNT PSA PUMP PZZA RRD RRGB RTRX SE SUPN SYX TIVO TNDM TOL VEEV WLL WMGI WTTR WTW

Wednesday (Feb 27)

• Morning:  AES AMRN AMT ANIP BBY CHK CLH CPB DF DNR DOC DY EYE FTDR GCP GTE HMLP HPT HZNP IONS LIVN LOW LXP MDCO MGPI MIDD NEWM NOVT OCN ODP PEG PGTI PNM RDC SBGI SHOO TAST TJX UTHR WAAS 
• Afternoon:  AEGN ALEX AMED ANSS APA ATSG AYX BEL BGNE BILI BKNG BOLD BOX CABO CCRN CHDN COLL CRC CVNA CWK DAR ECPG ERI ESTC ESV FG FIT FOE FTAI FTSI GEF GKOS HGV HHC HPQ ITRI KRA KW LADR LB LHCG MNST NNI ORBC PDCE PK PRAH PRGO PRSC QRTE.A SEMG SJI SOI SQ SRI SRPT STAY SWX TDOC TPC TROX TWNK UHS WIFI WING WTI XLRN

Thursday (Feb 28)

• Morning: AAON ABB ACIW AKRX AMCX AMRX BCPC BID BMCH BPMP BUD CARS CM CMD CNP CRAI CROX CWEN CWT DAVA DEA EGRX ENDP EXLS FOLD FRO FSS GOLF GTN GTS GTT HMHC HRI IBP ICPT IRDM JCP JD KDP LAUR LKQ MGLN MYE NLSN NOMD NRG OPI OXSQ PCRX PDCO PRIM PRTY SEAS SPAR STWD SYNH TD TRS TTI VAC VRTV VST
• Afternoon:  DDD ACHC AIMT ALRM AQN ALTR AMBC AMC APPF AGO ATRC ADSK EQH BIO BLDR CARG CSLT CISN SCOR DELL DCO EIX EDIT FTCH FNKO GCAP GPS GSBD HABT ICUI XON JAG KTOS LYV MAIN MAR MTZ MAXR MBI NKTR NPTN JWN NTNX PLYA PRAA PTCT PBYI PSTG KWR RDUS RBA RLJ SGMO SRG SWN SPPI SPLK SRCL RUN TRHC TCMD TERP TPIC UPWK VMW WDAY ZIXI ZGNX ZS WUBA 

Friday (March 1)

• Morning:  ASTE CLNY CORE XRAY EBIX FL KOP NWN PEGI PTLA SSP SNH STRA TGNA TRCO 

******

• Monday: December Wholesale Inventories (Briefing.com consensus 0.4%; prior 0.3%) at 10:00 ET; $40 bln 2-yr Treasury note auction results at 11:30 ET; and $41 bln 5-yr Treasury note auction results at 13:00 ET
• Tuesday: December S&P Case-Shiller Home Price Index (Briefing.com consensus 4.5%; prior 4.7%) at 8:00 ET; December Housing Starts (Briefing.com consensus 1254K; prior 1256K) and Building Permits (Briefing.com consensus 1290K; prior 1328K) at 8:30 ET; December FHFA Housing Price Index (prior 0.4%) at 9:00 ET; February Consumer Confidence (Briefing.com consensus 125.0; prior 120.2) at 10:00 ET; and $32 bln 7-yr Treasury note auction results at 13:00 ET
• Wednesday: Weekly MBA Mortgage Index (prior 3.6%) at 7:00 ET; January Advance Intl. Trade in Goods; Advance Retail Inventories; and Advance Wholesale Inventories at 8:30 ET; December Factory Orders (Briefing.com consensus 1.0%; prior -0.6%), Fed Chair Powell Semi-Annual Monetary Policy Testimony, and January Pending Home Sales (Briefing.com consensus -0.4%; prior -2.2%) at 10:00 ET; and Weekly EIA Crude Oil Inventories (prior +3.7M) at 10:30 ET
• Thursday: Q4 GDP - Advance (Briefing.com consensus 2.3%; prior 3.4%), Q4 GDP Deflator - Advance (Briefing.com consensus 1.7%; prior 1.8%), weekly Initial Claims (Briefing.com consensus 221K; prior 216K), and Continuing Claims (prior 1725K) at 8:30 ET; February Chicago PMI (Briefing.com consensus 57.5; prior 56.7) at 9:45 ET; and weekly EIA Natural Gas Inventories (prior -177 bcf) at 10:30 ET
• Friday: December Personal Income (Briefing.com consensus 0.3%; prior 0.2%), Personal Spending (Briefing.com consensus -0.2%; prior 0.4%), and January Personal Income (Briefing.com consensus 0.3%) at 8:30 ET; February ISM Manufacturing Index (Briefing.com consensus 56.0; prior 56.6), and Final February Michigan Consumer Sentiment (Briefing.com consensus 95.6; prior 95.5) at 10:00 ET

-=Jazz Pharmaceuticals (JAZZ) reported earnings on Tue 7 Aug 2018 (a/h)

Jazz Pharmaceuticals (JAZZ) stock dipped late Tuesday after the drugmaker topped second-quarter expectations but issued a 2018 profit outlook that lagged analyst views.

In late action on the stock market today, Jazz stock dipped 3.8% after closing up 1.9%, at 179.90. Shares are forming a flat base with a buy point at 184.10. Jazz is listed on both the IBD 50 and Leaderboard. It has a Composite Rating of 96 out of a best-possible 99, making it second out of 42 pharmaceutical stocks tracked by Investor's Business Daily.

For the second quarter, Jazz reported adjusted income of $3.49 per share on sales of $500.5 million, beating analyst expectations for $3.22 and $470 million, respectively. Adjusted income grew 36% while sales advanced 27% year over year.

Sales of narcolepsy drug Xyrem grew 19% to $356 million. Erwinaze, a cancer drug, advanced 20% to $58.7 million. The best growth came from Defitelio, which treats a liver condition. Defitelio sales generated $40.5 million, growing 34%. New cancer drug Vyxeos brought in $28 million.

Jazz projected $1.88 billion to $1.93 billion in total revenue, including $1.35 billion to $1.38 billion from Xyrem sales. The consensus modeled $1.9 billion in total revenue. Jazz's adjusted profit view for $12.75-$13.25 per share lagged analyst estimates by 10 cents at the midpoint.

ImmunoGen (IMGN) and Jazz Pharma (JAZZ) enter Into global collaboration

 

Immunogen and Jazz Pharmaceuticals (JAZZ) have entered into a collaboration granting Jazz rights to opt into development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs, as well as an additional program to be designated during the term of the agreement(6.46 )

ImmunoGen to receive a $75 million upfront payment, up to $100 million, over seven years, in research support, a co-commercialization option, and potential future opt-in fees, milestones and royalties.

• The programs covered under the agreement include IMGN779, a CD33-targeted ADC for the treatment of acute myeloid leukemia (AML) in Phase 1 testing, and IMGN632, a CD123-targeted ADC for hematological malignancies expected to enter clinical testing before the end of the year.
• Under the terms of the agreement, ImmunoGen will be responsible for the development of the three ADC programs prior to any potential opt-in by Jazz.
  • Following any opt-in, Jazz would be responsible for any further development as well as for potential regulatory submissions and commercialization.
• IMGN779 is a novel ADC that combines a high-affinity, humanized anti-CD33 antibody, a cleavable disulfide linker, and one of ImmunoGen's novel indolino-benzodiazepine payloads, called IGNs, which alkylate DNA without crosslinking, resulting in potent preclinical anti-leukemia activity with relative sparing of normal hematopoietic progenitor cells1,2. IMGN779 is in Phase 1 clinical testing for the treatment of AML.
• IMGN632 is a preclinical stage humanized anti-CD123 antibody-based ADC that is a potential treatment for AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN), myelodysplastic syndrome, B-cell acute lymphocytic leukemia, and other CD123-positive malignancies. IMGN632 uses a novel payload, linker, and antibody technology and in AML xenograft models has demonstrated a large therapeutic index3.
• ImmunoGen expects to file an investigational new drug application (IND) for IMGN632 this quarter and enroll the first patient in a Phase 1 study before the end of the year.